Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Women of all ages will get round-the-clock access to comprehensive treatment
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
LG Chem will receive totaling up to $95.5 million for the China rights
This one-of-a-kind ophthalmic subspecialty division is focused on the treatment of the eye condition glaucoma
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
The new eye hospital in Vashi is ASG’s second in the Mumbai Metropolitan Region (MMR) and the sixth in Maharashtra
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Subscribe To Our Newsletter & Stay Updated
